Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Payables (2016 - 2025)

CorMedix (CRMD) has disclosed Payables for 13 consecutive years, with $7.9 million as the latest value for Q4 2025.

  • Quarterly Payables rose 358.37% to $7.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.9 million through Dec 2025, up 358.37% year-over-year, with the annual reading at $7.9 million for FY2025, 358.37% up from the prior year.
  • Payables hit $7.9 million in Q4 2025 for CorMedix, down from $20.5 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $20.5 million in Q3 2025 to a low of $943344.0 in Q2 2021.
  • Historically, Payables has averaged $3.5 million across 5 years, with a median of $2.2 million in 2022.
  • Biggest five-year swings in Payables: crashed 60.69% in 2021 and later soared 1422.09% in 2025.
  • Year by year, Payables stood at $2.2 million in 2021, then dropped by 0.34% to $2.2 million in 2022, then increased by 8.35% to $2.4 million in 2023, then fell by 27.92% to $1.7 million in 2024, then skyrocketed by 358.37% to $7.9 million in 2025.
  • Business Quant data shows Payables for CRMD at $7.9 million in Q4 2025, $20.5 million in Q3 2025, and $5.8 million in Q2 2025.